New York, Jan 16, 2026, 20:00 ET — Market closed.
- Boston Scientific shares slipped 2.18% to close at $88.07, marking their seventh straight session of losses.
- Investors are digesting the $14.5 billion Penumbra deal alongside the near-term earnings hit flagged by management.
- U.S. markets remain closed Monday in observance of MLK Day. Boston’s next key event is the earnings call scheduled for Feb. 4.
Boston Scientific Corporation (BSX) shares dropped 2.18% on Friday, closing at $88.07. It marked their seventh consecutive day of declines, with volume heavier than usual. The S&P 500 slipped 0.06%, the Dow fell 0.17%, and competitors Abbott and Medtronic also finished in the red. 1
Shares slid after Boston Scientific revealed plans to acquire Penumbra (PEN) for $14.5 billion, marking its largest purchase in 20 years as it seeks to expand in clot-removal and neurovascular devices. CEO Mike Mahoney hailed the deal as a “home run” during an analyst call. Still, J.P. Morgan analysts warned it could draw “significant investor scrutiny,” while Truist’s Richard Newitter noted it plugs a key gap in Boston’s neurovascular lineup. 2
U.S. stock and bond markets will shut down Monday in observance of Martin Luther King Jr. Day, reopening for regular trading on Tuesday. That means Boston’s deal math—and investors’ appetite for big medtech M&A—won’t get sorted until after the long weekend. 3
On Thursday, a filing revealed that Boston Scientific and Penumbra finalized a definitive agreement. Boston Scientific also held a conference call and uploaded an investor presentation to its website.
Boston announced it will pay $374 per Penumbra share in a cash-and-stock deal that values the company at about $14.5 billion. Shareholders can choose between $374 in cash or 3.8721 Boston Scientific shares, subject to proration, with an expected split of roughly 73% cash and 27% stock. Boston plans to finance around $11 billion of the cash portion using existing funds and new debt. The company said the acquisition will lower adjusted earnings per share—a profit metric excluding certain items—by $0.06 to $0.08 in the first year post-close, before turning neutral or potentially accretive. Mahoney described the deal as “an opportunity to enter new, fast-growing segments within the vascular space,” while Penumbra CEO Adam Elsesser expressed eagerness to “unite our efforts” with Boston. 4
Penumbra’s key offerings focus on mechanical thrombectomy — minimally invasive procedures that clear blood clots via catheter — and embolization, which involves blocking blood flow to stop bleeding or seal vessels. These areas are expanding rapidly, though they bring high demands.
Several analysts saw the price as justified by the strategic alignment. BTIG’s Ryan Zimmerman highlighted that the acquisition would provide Boston with a growth driver in thrombectomy and embolization. RBC Capital Markets’ Shagun Singh added that Penumbra “has been considered a take-out candidate for some time now,” pointing to increased activity in the sector since Stryker’s Inari deal last year. 5
BSX holders face a key question: can the company fund growth without sacrificing flexibility? Taking on new debt ups the stakes. Boston is already warning investors to brace for an earnings drop before the deal kicks in.
The deal still faces the usual hurdles. It requires approval from Penumbra shareholders and must meet standard closing conditions. Timelines often slip, particularly if regulators dig deeper.
Boston Scientific’s stock won’t trade again until Tuesday, skipping Monday. Investors are eager for updates on financing, any moves from rating agencies, and to see if the selloff steadies following the first major medtech deal of the year.
Boston Scientific is set to release its fourth-quarter results on Feb. 4, with a call scheduled for 8:00 a.m. ET. This will probably be the next opportunity for management to address detailed questions on leverage, integration, and the timeline for Penumbra’s shift from dilutive to accretive. 6
